The study of serum proteomics in the early diagnosis of gastric cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036003

Enrollment

Unknown

Registered

2020-08-21

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Gold Standard:Pathologic diagnosis

Index test:Serum proteomics

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Experimental group (gastric cancer patients): (1) Patients with gastric adenocarcinoma or gastroesophageal junction who were diagnosed by preoperative gastroscopy and biopsy (pathological sections from other hospitals shall be confirmed by pathological consultation in our hospital); (2) The patient is between 18 and 85 years old; (3) There was no preoperative chemotherapy, radiotherapy or targeted therapy. Control group (Normal people) : (1) No tumor lesions were identified by gastroscopy; (2) Between the ages of 18 and 85 years; (3) No history of gastric surgery; (4) No history of tumor.

Exclusion criteria

Exclusion criteria: Experimental group (gastric cancer patients) (1) Preoperative examination revealed other malignant tumors; (2) Previous history of other malignant tumors; (3) Stump gastric cancer.

Design outcomes

Primary

Measure	Time frame
serum proteomics;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactLi Haojie

Zhongshan Hospital, Fudan University

li.haojie@zs-hospital.sh.cn+86 021-64041990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026